Postprandial effects of alirocumab on lipemia and inflammtion

INTERVENTION: 9 weeks treatment with either biweekly alirocumab 150 mg or bikweeekly matching placebo. Before and after treatment oral fat loading test (OFLT). CONDITION: Postprandial lipemia, Diabetes Mellitus Type 2 (DM type II) ; ; PRIMARY OUTCOME: Primary endpoint is effect of alirocumab on postprandial leukocyte activation markers (CD11b, CD66b and CD35). SECONDARY OUTCOME: Secondary endponts are the effect of 9 weeks of treatment with alirocumab on postprandial lipemia (apoB48, triglycerides, free fatty acids and b‐hydroxybutyrate), oxidative stress (myeloperoxidase) and vascular function (arterial pulse wave velocity and arterial pulse wave analysis). INCLUSION CRITERIA: • Age of 18 years of older; • Male • Diabetes mellitus type 2 on intensive insulin treatment (three times short acting and once daily long acting) (unchanged for > 10 weeks prior to consent) • Stable glucose regulation last 6 months (HbA1c > 6.5% ‐ < 9.0%) • Stable lipid lowering therapy last 2 months (no changes in regiment or dose)